Status In progress
Process STA
ID number 1019

Provisional Schedule

Expected publication 17 January 2018

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Merck Sharp & Dohme (pembrolizumab)
Others Department of Health
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (CAU not returned, not participating)
  Actavis UK (CAU not returned, not participating)
  Dr Reddy's Laboratories (CAU not returned, not participating)
  Eli Lilly (CAU not returned, not participating)
  Hospira (CAU not returned, not participating)
  Medac (CAU not returned, not participating)
  Peckforton Pharmaceuticals (CAU not returned, not participating)
  Sanofi (CAU not returned, not participating)
  Seacross Pharmaceuticals (CAU not returned, not participating)
  Sun Pharmaceuticals UK (CAU not returned, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute

Timeline

Key events during the development of the guidance:

Date Update
26 October 2017 Committee meeting: 2
03 August 2017 - 24 August 2017 Appraisal consultation
17 August 2017 The company has requested to submit additional evidence to this appraisal which NICE have agreed to accept. As a consequence, to allow time for this to be reviewed, this will no longer be discussed at the technology appraisal committee meeting on 30 August 2017. The discussion has now been rescheduled to 26 October 2017.
31 May 2017 Committee meeting: 1
08 December 2016 Invitation to participate
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance